Primary Hyperaldosteronism
14
2
3
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 14 trials
100.0%
+13.4% vs benchmark
7%
1 trials in Phase 3/4
0%
0 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 10 completed trials
Clinical Trials (14)
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
[18F]AlF-NOTA-pentixather PET/CT in Patients With Suspected Primary Hyperaldosteronism
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
Tissue K+ in Primary Hyperaldosteronism
HyperAldosteronism in Pregnancy Predicted Impacts (H.A.P.P.I. Trial)
Dynamic Hormone Diagnostics in Endocrine Disease
Radiofrequency Endoscopic Ablation With Ultrasound Guidance: a Non-surgical Treatment for Aldosterone-producing Adenomas
A Prospective Cohort Study for Patients With Adrenal Diseases
11C-Metomidate PET Versus Adrenal Vein Sampling in Primary Aldosteronism
Primary Hyperaldosteronism and Ischemia-reperfusion Injury
Study of Myocardial Interstitial Fibrosis in Hyperaldosteronism
Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment
Intraoperative Analysis of Cortisol During Adrenal Vein Sampling
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism